Toll Free : + 1-888-961-4454 | Int'l : + 91 (788) 802-9103 | support@researchdive.com
LI23078755 |
Pages: 270 |
Jul 2023 |
The medicinal products used in diagnostic imaging procedures, such as X-rays, CT scans, MRI scans, and ultrasound, to improve the visibility of tissues and organs are referred to as contrast media. The accuracy of medical diagnosis is increased by the use of contrast media, commonly referred to as contrast agents or imaging agents, which help distinguish between normal and pathological tissues. Iodinated contrast agents (used in X-rays and CT scans), gadolinium-based contrast agents (used in MRI scans), and microbubble contrast agents (used in ultrasound imaging) are three general categories of contrast media. Different contrast mediums have different properties and uses.
The global contrast media market size was $5,933.4 million in 2022 and is predicted to grow with a CAGR of 3.5%, by generating a revenue of $8,363.3 million by 2032.
The number of elective operations and non-urgent diagnostic imaging examinations, especially those needing contrast media, significantly decreased as a result of the pandemic. In order to manage the surge of COVID-19 patients, several hospitals and imaging facilities redirected their resources, which led to the postponement or cancellation of non-emergency treatments. The demand for diagnostic imaging treatments gradually increased as the situation got better and medical facilities resumed their regular activities. The need to deal with the backlog of postponed treatments and the understanding of the significance of prompt and correct diagnosis in managing patients' overall healthcare were the driving forces behind this recovery.
There is anticipated to be a resurgence in demand for diagnostic imaging treatments when healthcare systems restart regular operations and clear the backlog of postponed procedures. Given that contrast agents are essential to many imaging tests, this increasing demand would also result in a greater need for contrast media. The significance of early disease identification and diagnosis has been made clear by the COVID-19 pandemic. Proactive healthcare management is valued by both patients and healthcare practitioners. It is anticipated that the focus on early detection would increase demand for diagnostic imaging procedures, especially those that make use of contrast media, as these techniques are essential for identifying and tracking a variety of disorders.
The market for contrast media is being driven by technological developments in medical imaging modalities as X-ray, CT scan, MRI, and ultrasound. These developments have enhanced image quality, increased resolution, sped up scanning durations, and enabled the collection of molecular and functional data. Healthcare workers can obtain clearer, more detailed images using contrast media, which helps them make accurate diagnosis. The market for contrast media is significantly influenced by the increased incidence of chronic diseases like cancer, neurological problems, and cardiovascular ailments. Diagnostic imaging treatments are frequently needed for certain disorders in order to help with their diagnosis, staging, and monitoring. Contrast media make tissues and organs more visible, making it possible to spot anomalies precisely and quickly. The global increase in the number of diagnostic imaging operations is a major market driver for contrast media. The ageing of the population, the increased prevalence of chronic diseases, and the growing understanding of the value of early disease identification and screening are all factors that contribute to this rise. The need for contrast material increases as there are more imaging tests performed. These factors are anticipated to boost the contrast media market growth in the coming years.
To know more about global contrast media market drivers, get in touch with our analysts here.
The market may be significantly constrained by adverse reactions to contrast media. Even while these reactions are uncommon, some individuals may experience severe problems as a result. Contrast media use may be restricted due to safety issues and the possibility for adverse effects, particularly in individuals with pre-existing diseases or those who are at a higher risk. Regulating agencies including the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) have set strict controls and standards on the contrast media industry. For manufacturers, observing these laws and regulations, which cover safety, efficacy, and quality standards, can be difficult and time-consuming. The availability and commercialization of new contrast media products may be impacted by the regulatory environment. Particularly in areas with constrained healthcare budgets or where patients are required to cover a considerable amount of costs, the price of contrast media and the associated diagnostic imaging procedures can be a significant barrier. The cost and use of contrast media may also be impacted by insurance companies' reimbursement guidelines and coverage restrictions. These factors are anticipated to restrain the contrast media market share in the coming years.
The market for contrast media is being driven by technological developments in medical imaging modalities. Future advancements in imaging technology, including higher-resolution scanners, quicker image acquisition, and the integration of functional and molecular imaging capabilities, will present opportunities for the creation of novel contrast media formulations that will improve diagnostic precision. The market for contrast media has prospects as a result of the shift towards precision imaging and personalized therapy. More individualized and precise diagnoses can result from adjusting imaging techniques and contrast media based on patient features such genetic make-up, biomarkers, and disease subtype. Significant growth potential may be provided by the development of contrast media that enable personalized imaging techniques. A promising new area for the contrast media business is theragnostic, which combines therapeutic interventions and diagnostic imaging. Contrast agents may be created to distribute therapeutic agents or make it easier to deliver drugs to specific areas of the body. More accurate treatment planning and monitoring may be made possible by the combination of contrast media with image-guided therapies. These factors are anticipated to have positive impact on contrast media market opportunities in the coming years.
To know more about global contrast media market opportunities, get in touch with our analysts here.
The X-ray/computed tomography sub-segment accounted for the highest share in 2022. Contrast media are used in X-ray imaging to enhance the visibility of particular organs or structures. Iodine- and barium-based contrast agents are the most frequently utilized X-ray contrast materials. They are often given intravenously for vascular and organ imaging or orally or rectally for gastrointestinal examinations. Contrast media are used in X-ray techniques to distinguish between blood arteries, highlight anomalies, and identify ailments such gastrointestinal disorders, vascular conditions, or problems with the kidneys and urinary system. Angiography, hysterosalpingography, and intravenous urography are a few X-ray investigations that make use of contrast agents. X-rays are used in CT scans to create cross-sectional images of the human body. In CT, contrast media are frequently used to make blood arteries, organs, and tumors more visible. Iodine has excellent X-ray attenuation qualities, making iodine-based contrast agents the most popular contrast agents used in CT scans. Contrast media aid in the detection and diagnosis of many illnesses by improving the visualization and characterization of structures in CT imaging. CT examinations that typically use contrast media include CT angiography, CT urography, and CT enterorrhaphy.
The iodinated sub-segment accounted for the highest market size in 2022. The market for iodinated contrast media includes a variety of product types that are used to improve image contrast during medical imaging procedures and contain iodine compounds. The earliest kind of iodinated contrast media were ionic contrast agents. They have a higher osmolality and include both positively and negatively charged ions, which can result in more side effects and unpleasant reactions. Nowadays, ionic contrast media are employed less frequently because to their higher hazards. The market for iodinated contrast media has significantly advanced in recent years thanks to the creation of new, safer formulations. These improvements aim to increase patient comfort and diagnostic precision while reducing the likelihood of unpleasant responses.
The neurological disorder sub-segment accounted for the highest share in 2022. Contrast-enhanced MRI is useful in the diagnosis and characterization of brain tumors, vascular malformations, multiple sclerosis (MS) lesions, and inflammatory diseases in neurological disorders. It provides crucial information for diagnosis, treatment planning, and disease progression tracking by separating aberrant tissue from healthy tissue. In situations like acute stroke assessment, evaluation of cerebral hemorrhages, and detection of vascular anomalies like aneurysms or arteriovenous malformations (AVMs), contrast-enhanced CT is frequently used. It offers comprehensive knowledge of the circulatory systems and aids in the planning of interventions or surgeries.
The North America region accounted for the highest share in 2022. The market for contrast media is significantly dominated by North America. The presence of a sizable patient population, a well-developed healthcare system, and high healthcare spending are some of the contributing causes to the region's market supremacy. The desire for sophisticated imaging procedures, the increased prevalence of chronic diseases, and the emphasis on early disease identification and prevention have all contributed to the steady rise of the contrast media market in North America. The development of the market has also been aided by technological developments and the introduction of new contrast agents.
Merger & acquisition and product launches are common strategies followed by major market players. Some of the leading contrast media market players are Bayer AG, General Electric Company, Bracco Diagnostic, Inc., Nano Therapeutics Pvt. Ltd., Guerbet, iMax, Trivitron Healthcare, Lantheus Medical Imaging, Inc., Unijules Life Sciences, J.b. and Chemicals & Pharma.
Aspect | Particulars |
Historical Market Estimations | 2021 |
Base Year for Market Estimation | 2022 |
Forecast Timeline for Market Projection | 2023-2032 |
Geographical Scope | North America, Europe, Asia-Pacific, and LAMEA |
Segmentation by Modality |
|
Segmentation by Product type |
|
Segmentation by Application |
|
Key Companies Profiled |
|
* Taxes/Fees, If applicable will be added during checkout. All prices in USD.
Have a question ?
Enquire To BuyNeed to add more ?
Request Customization